D’une gestion optimale des échantillons osseux à une prise en charge de qualité des malades en 2022 : un nouveau paradigme
暂无分享，去创建一个
F. Le Loarer | J. Guinebretière | S. Aubert | F. Larousserie | C. Bouvier | C. Galant | A. Gomez-Brouchet | E. Miquelestorena-Standley | Matthias Tallegas | G. de Pinieux
[1] A. Stenzinger,et al. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer , 2021, The journal of pathology. Clinical research.
[2] Chuangang Tang,et al. Incidence, prevalence, and outcomes of systemic malignancy with bone metastases , 2020, Journal of orthopaedic surgery.
[3] S. Aubert,et al. Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples , 2020, Modern Pathology.
[4] B. Alexander,et al. Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA , 2019, Blood.
[5] A. Flanagan,et al. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing , 2019, Genes, chromosomes & cancer.
[6] S. Aubert,et al. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions , 2013, Modern Pathology.
[7] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.